Clinical Trial Update: A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study [Phase 3]

View source ↗

Summary

This Phase 3 trial update notes the completion of a study evaluating TMC435 in combination with peginterferon alfa-2a and ribavirin in hepatitis C genotype-1 pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)
• TMC435

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED